Another trial testing CDK4/6i in the adjuvant setting is the MonarchE trial, which evaluated the addition of 2 years of adjuvant abemacicilb to standard ET in hormone receptor positive, HER2-negative early BC patients who were at high risk of relapse after surgery [20]. This evidence concerns the gene ERBB2 and breast cancer.